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Abstract
Background:  The seroprevalence of hepatitis C varies substantially between countries and
geographic regions. A better understanding of the seroprevalence of this disease, and the risk
factors associated with seropositive status, supply data for the development of screening programs
and provide insight into the transmission of the disease. The purpose of this investigation was to
determine the seroprevalence of hepatitis C and associated risk factors in an urban population in
Haiti.
Methods:  A prospective survey for hepatitis C antibodies was conducted among an urban
outpatient population in Cap-Haïtien, Haiti, with a sample size of 500 subjects. An anonymous 12
question survey, with inquiries related to demographic characteristics and risk factors for HCV
acquisition, was concomitantly administered with testing. These demographic and behavioral risk
factors were correlated with HCV antibody status using univariate and multivariate tests.
Results: The prevalence of positive HCV antibody was 22/500 (4.4%). Subjects that were anti-
HCV positive had an average of 7 ± 8.6 lifetime sexual partners, compared to average of 2.5 ± 3.5
lifetime sexual partners among HCV-negative subjects (p = 0.02). In a multiple logistic regression
model, intravenous drug use (OR 3.7, 1.52–9.03 95% CI) and number of sexual partners (OR 1.1,
1.04–1.20 95% CI) were independently associated with a positive HCV antibody result.
Conclusions:  A substantial number of subjects with HCV antibodies were detected in this
population in Haiti. Further investigation into the correlation between the number of sexual
partners and testing positive for hepatitis C antibodies is indicated.
Background
The seroprevalence of hepatitis C virus (HCV) varies sub-
stantially in different geographic regions throughout the
world [1]. Prior studies have suggested a low prevalence of
HCV antibodies among a sample of patients in rural Haiti
[2]. No cases of positive HCV antibody were detected
among 485 patients in a sexually transmitted infections
clinic in Jamaica [3], but 41% of hemophiliacs in Jamaica
were HCV antibody positive [4]. Our hypothesis was that
a higher prevalence of HCV antibodies would be detected
in an urban population in Haiti.
Risk factors associated with HCV serologic status may be
specific to a country or region. In particular, the role of
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sexual contact in the transmission of HCV appears to be
influenced by characteristics and location of the popula-
tion studied [5]. Therefore, examination of the risk factors
associated with the presence of HCV antibodies in this
population can be utilized to guide screening procedures
as well as provide insight into the transmission of HCV in
the context of Haitian society. A better understanding of
the transmission of HCV could enhance the effectiveness
of prevention efforts. This research study provides analysis
of risk factors associated with hepatitis C from a popula-
tion that had not been previously studied. We have
observed a seroprevalence rate of 4.4% (22/500) of HCV
antibodies, with intravenous drug usage and the number
of sexual partners being associated with positive HCV
antibodies.
Methods
The study was approved by the Institutional Review Board
at Brooke Army Medical Center (Fort Sam Houston,
Texas). Subjects were recruited in the year 2000 from a
healthy population utilizing hospital and clinic services in
Cap-Haïtien, Haiti, which is the second largest city in the
country. Subjects were recruited on presentation to the
hospital laboratory for blood draws for routine laboratory
tests. This laboratory was the only location in which sub-
jects were recruited and samples obtained. Subject partic-
ipation was not limited to a particular medical condition.
The first 500 subjects that agreed to participate in the
study were enrolled. These subjects were presenting to the
hospital for services, and were not patients in a specific
clinic. After informed consent was obtained, subjects
completed a written 12 question survey in Creole, at the
same location as where the blood was drawn. The subjects
completed the survey by themselves. The questionnaire
focused on demographic information and topic areas pos-
sibly associated with transmission of hepatitis C (intrave-
nous drug use, intranasal cocaine use, blood transfusions,
sexual history, number of tattoos). Intravenous drug use
and cocaine use was measured on a 0–3 scale (never-rare-
frequent-daily). Blood transfusions, number of sexual
partners, age of first sexual intercourse and number of tat-
toos were quantified. Serum was obtained for testing for
HCV antibody, utilizing the Abbott HCV EIA 3.0 kit™
(Abbott Laboratories, Abbott Park, Illinois). The survey
information and serum results were identified only by a
subject identification number, with all other identifying
information removed.
Data were analyzed using univariate correlations with a
Pearson's correlation coefficient. The number of sexual
partners was compared between HCV-positive and nega-
tive subjects using an independent-sample t-test. Intrave-
nous drug use between HCV-seropositive and
seronegative subjects was compared using a Fisher's exact
test. A multivariate logistic regression model was
employed with stepwise backward elimination of non-sig-
nificant variables, with HCV antibody status as the
dependent variable. All of the variables from the survey
were included in the model.
Results
A total of 500 subjects were recruited and had serum
tested for HCV antibody. Only two of these subjects did
not complete the survey. Most subjects who were
informed of the study agreed to participate, but an exact
number of subjects who refused participation in the study
was not determined. The background characteristics of the
patient population are displayed in Table 1. Of note, few
subjects (12/496) admitted intravenous drug use, and
only one subject noted having a tattoo.
The prevalence of positive HCV antibodies was 22/500
(4.4%, 95% CI 2.6–6.2%). Subjects that were anti-HCV
positive had an average of 7 ± 8.6 lifetime sexual partners,
compared to average of 2.5 ± 3.5 lifetime sexual partners
among HCV-negative subjects (p = 0.02). There were no
other statistically significant differences between the HCV
antibody-positive and HCV antibody-negative groups in
terms of demographic characteristics or topic areas
associated with HCV infection/transmission. Among sub-
jects with HCV antibodies, 4/22 subjects admitted intrave-
nous drug use compared to 8/476 among HCV-antibody
negative subjects (p < 0.001). A similar result was
observed for rates of intranasal cocaine use among HCV-
antibody positive (4/22) vs. HCV-antibody negative (8/
474) subjects (p < 0.001). Of the 22 subjects with positive
HCV antibodies, 12 subjects denied intravenous drug use,
had no tattoos, and had either 1 or 2 lifetime sexual part-
ners. Five subjects with positive HCV antibodies denied
intravenous drug use and had >10 lifetime sexual
partners.
Intravenous drug use (r = 0.26, p < 0.001), intranasal
cocaine use (r = 0.29, p < 0.001) and the number of life-
Table 1: Characteristics and survey responses of recruited 
subjects
Characteristic Frequency
Sex- % males 332/498 (67%)
Age (mean ± SD in years) 33.7 ± 15.9
Years of Education (mean ± SD) 7.8 ± 5.7
Marital Status- % married 152/495 (31%)
Age of First Sexual Intercourse (mean ± SD in years) 19.1 ± 5.7
Number of Lifetime Sexual Partners (mean ± SD) 2.7 ± 4.0
Intravenous Drug Use- % with any history of usage 12/498 (2%)
Intranasal Cocaine Use- % with any history of usage 12/496 (2%)
Subjects with tattoos 1/498BMC Gastroenterology 2004, 4:31 http://www.biomedcentral.com/1471-230X/4/31
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time sexual partners (r = 0.24, p < 0.001) were the only
three variables with a statistically significant correlation
with the presence of HCV antibodies on univariate analy-
sis. The number of lifetime sexual partners had some cor-
relation with intravenous drug use (r = 0.12, p = 0.009)
and intranasal cocaine use (r = 0.13, p = 0.004). There was
a very close correlation between intravenous drug use and
intranasal cocaine use (r = 0.99, p < 0.001). Therefore,
intranasal cocaine use was not incorporated into the mul-
tivariate model due to concerns about co-linearity. In the
multiple logistic regression model with backwards elimi-
nation, intravenous drug use (OR 3.7, 1.52–9.03 95% CI)
and number of sexual partners (OR 1.1, 1.04–1.20 95%
CI) were independently associated with a positive HCV
antibody result.
Discussion
We observed a prevalence of 4.4% of HCV antibodies in
an urban population in Haiti. Additionally, we found that
HCV antibodies were associated with intravenous drug
use as would be expected, but also with increasing
number of lifetime sexual partners. It is conceivable that
subjects who reported higher number of sexual partners
were more likely not to admit past intravenous drug
usage. However, it is also possible that this finding repre-
sents sexual transmission of hepatitis C among subjects
with multiple prior sexual partners. Finally, we observed
HCV antibodies were present is some subjects who denied
intravenous drug use and had less than 3 lifetime sexual
partners.
A recent survey of the influences on HIV preventive behav-
iors among youth in Haiti observed that 80% of males
and 42% of females self-disclosed sexual activity [6]. This
survey noted a mean age of first intercourse of 13.1 years,
a number lower than our observations (19.1 years). This
study also noted that condom use was infrequent in the
surveyed population (18% of subjects reported always or
sometimes using a condom), while 43% reported 3 or
more lifetime sexual partners. The applicability of these
data to our study population is limited because the age
difference between this population and the population of
our study. Although the results of this investigation do not
directly describe the population of our study, we might
extrapolate that our population would be unlikely to have
a high rate of condom usage.
Only a single prior study in Haiti suggested that HCV anti-
bodies were rare [2]. The most obvious difference between
our results and this prior study was that the previous study
was performed on rural subjects, while our data was col-
lected in an urban setting. It is possible that intravenous
drug abuse would be more prevalent in an urban environ-
ment, which could partially explain the observed differ-
ences in seroprevalence. The previous study was also
conducted more than 10 years before our research.
Intravenous drug use does not exclusively explain the
prevalence of HCV antibodies in the studied population.
Although intravenous drug use was associated with an
increased likelihood of having HCV antibodies (as has
been thoroughly documented [1]), only four of the 22
subjects with HCV antibodies admitted drug use. Addi-
tionally, none of the HCV positive subjects had tattoos.
These findings suggest either that self-reported drug use
underestimates the prevalence of drug use in the popula-
tion, or another mode of transmission of HCV has
occurred.
The degree to which sexual transmission of HCV occurs is
exceedingly controversial [5,7]. Studies in monogamous
relationships suggest that sexual transmission of hepatitis
C occurs very rarely [8]. Seroprevalence studies from sexu-
ally-transmitted diseases clinics describe a variable
amount of HCV positive subjects, which tends to be low
when injection drug users are excluded [9,10]. The
number of sexual partners has been previously associated
with increasing risk of HCV exposure [11]. We also
observed the association between increasing number of
sexual partners and the likelihood of having HCV anti-
bodies. This association was observed even when control-
ling for other variables in a multivariate model. Our data
suggest that sexual transmission of hepatitis C may occur
more frequently in persons with multiple sexual partners.
However, additional larger studies directed at evaluating
HCV-infected persons with multiple sexual partners are
needed. All studies on the sexual transmission of hepatitis
C (including our study) are limited by the potential of the
confounding variable of shared toothbrushes, razor
blades and other items among sexual partners.
Our findings are limited by the lack of information
regarding active HCV infection. The presence of HCV anti-
bodies only indicates prior exposure, and definitive docu-
mentation of active HCV infection requires detection of
virus in the bloodstream utilizing HCV RNA polymerase
chain reaction testing. However, since most patients
exposed to hepatitis C develop chronic infection [12],
HCV antibody testing provides a reasonable estimate of
the amount of HCV infection in a population. Other lim-
itations of the study are linked to the difficulties inherent
in self-reporting of behaviors such as sexual activity and
drug use. Additionally, we were unable to obtain informa-
tion on subjects that refused participation in the study,
which may limit the representativeness of this population.
It is also possible that the patients receiving blood draws
in the Cap-Haïtien health clinic may not be representative
of the population of Haiti, or even the urban population
of Haiti. Finally, there are other possible alternativePublish with BioMed Central    and   every 
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sources of percutaneous exposure to HCV, such as medi-
cal injections by alternative practitioners or other medical,
surgical or dental procedures.
In conclusion, we provide seroprevalence data of HCV
antibodies in an urban population in Haiti. These data are
useful for understanding the risks of transfusion in Haiti
if the blood has not been previously screened for HCV.
This information contributes to our understanding of the
worldwide prevalence of hepatitis C, which allows for
informed decisions regarding the priorities of funding for
the treatment and prevention of this infection. Addition-
ally, we observed the number of sexual partners may be
related to a greater likelihood of having HCV antibodies,
but some subjects who denied intravenous drug use and
had few lifetime sexual partners still had HCV antibodies.
These findings could be utilized to foster consideration of
new studies into some of the risk factors that are not
clearly understood (such as procedures by medical, dental
or alternate practitioners). These results suggest that fur-
ther study into the mode of transmission of hepatitis C
should focus on patients with a high number of lifetime
sexual partners but no evidence of intravenous drug use.
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